{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:36:17Z","timestamp":1785245777143,"version":"3.55.0"},"reference-count":16,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"abstract":"<jats:p>Cefuroxime axetil has been shown to have efficacy comparable to doxycycline in adults with early Lyme disease (LD). Because of toxicity, doxycycline is usually avoided in children. For children who are unable to tolerate amoxicillin, there is currently no proven alternative oral therapy for LD. This randomized, unblinded study compared 2 dosage regimens of cefuroxime axetil (20 mg\/kg\/d and 30 mg\/kg\/d) with amoxicillin (50 mg\/kg\/d), each given for 20 days. Children were enrolled if they were 6 months to 12 years of age, had erythema migrans, and met other eligibility requirements. Serologic testing occurred at entry and after 6 months. Follow-up evaluations for safety, tolerability, and efficacy occurred at 10 and 20 days, 6 months, and 1 year. Forty-three children were randomized (13 in the amoxicillin group, 15 in each cefuroxime axetil group); 39 completed 12 months of follow-up. At the completion of treatment, there was total resolution of erythema migrans in 67% of the amoxicillin group, 92% of the low-dose cefuroxime group, and 87% of the high-dose cefuroxime group, and resolution of constitutional symptoms occurred in 100%, 69%, and 87%, respectively. All patients had a good outcome, with no long-term problems associated with LD. One patient, who was well at the first 2 follow-up visits, was treated with doxycycline because of new constitutional symptoms. Mild diarrhea occurred in a small number of participants in each group (1 patient was diagnosed and treated for Clostridium difficile-associated diarrhea, which occurred after completing the full course of study medication). No hypersensitivity reactions occurred. The number of patients in this trial was not sufficient to demonstrate a statistically significant difference between the 3 groups; however, both amoxicillin and cefuroxime axetil seem to be safe, efficacious treatments for children with early LD.<\/jats:p>","DOI":"10.1542\/peds.109.6.1173","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"1173-1177","source":"Crossref","is-referenced-by-count":68,"title":["Comparative Study of Cefuroxime Axetil Versus Amoxicillin in Children With Early Lyme Disease"],"prefix":"10.1542","volume":"109","author":[{"given":"Stephen C.","family":"Eppes","sequence":"first","affiliation":[{"name":"Alfred I. DuPont Hospital for Children, Wilmington, DE 19899"},{"name":"Jefferson Medical College, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Childs","sequence":"additional","affiliation":[{"name":"Alfred I. DuPont Hospital for Children, Wilmington, DE 19899"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,6,1]]},"reference":[{"key":"2021121006223480800_R1","doi-asserted-by":"crossref","unstructured":"Falagas ME, Gorbach SL. IDCP practice guidelines. Infect Dis Clin Pract.1996;5:217\u2013225","DOI":"10.1097\/00019048-199605000-00002"},{"key":"2021121006223480800_R2","doi-asserted-by":"crossref","unstructured":"Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis.2000;31(suppl 1)S1\u2013S14","DOI":"10.1086\/314053"},{"key":"2021121006223480800_R3","unstructured":"American Academy of Pediatrics. Lyme disease. In: Abramson J, ed. 2000 Red Book. 25th ed. Elk Grove Village, IL: AmericanE Academy of Pediatrics; 2000:377"},{"key":"2021121006223480800_R4","doi-asserted-by":"crossref","unstructured":"Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet.1990;336:1404\u201306","DOI":"10.1016\/0140-6736(90)93103-V"},{"key":"2021121006223480800_R5","doi-asserted-by":"crossref","unstructured":"Massorotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med.1992;92:396\u2013403","DOI":"10.1016\/0002-9343(92)90270-L"},{"key":"2021121006223480800_R6","doi-asserted-by":"crossref","unstructured":"Steere AC, Levin RE, Mulloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum.1994;37:878\u2013888","DOI":"10.1002\/art.1780370616"},{"key":"2021121006223480800_R7","doi-asserted-by":"crossref","unstructured":"Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease. Ann Intern Med.1992;117:273\u2013280","DOI":"10.7326\/0003-4819-117-4-273"},{"key":"2021121006223480800_R8","doi-asserted-by":"crossref","unstructured":"Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother.1995;39:661\u2013667","DOI":"10.1128\/AAC.39.3.661"},{"key":"2021121006223480800_R9","doi-asserted-by":"crossref","unstructured":"Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother.1993;37:1444\u20131446","DOI":"10.1128\/AAC.37.7.1444"},{"key":"2021121006223480800_R10","doi-asserted-by":"crossref","unstructured":"Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother.1990;34:2133\u20132136","DOI":"10.1128\/AAC.34.11.2133"},{"key":"2021121006223480800_R11","doi-asserted-by":"crossref","unstructured":"Powell DA, James NC, Ossi MJ, Nahata MC, Donn KH. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother.1991;35:2042\u20132045","DOI":"10.1128\/AAC.35.10.2042"},{"key":"2021121006223480800_R12","unstructured":"Fawcett PT, Rose CD, Gibney KM, Doughty RA. Frequency and specificity of antibodies which cross-react with Borrelia burgdorferi antigens. J Rheumatol.1992;19:582\u2013587"},{"key":"2021121006223480800_R13","unstructured":"Fawcett PT, Rose CD, Gibney KM. Comparative evaluation of adsorption with E coli on ELISA tests for Lyme borreliosis. J Rheumato.l1995;22:684\u2013688"},{"key":"2021121006223480800_R14","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988"},{"key":"2021121006223480800_R15","doi-asserted-by":"crossref","unstructured":"Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children given early treatment. J Pediatr.1993;122:591\u2013593","DOI":"10.1016\/S0022-3476(05)83541-3"},{"key":"2021121006223480800_R16","doi-asserted-by":"crossref","unstructured":"Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL, for the Pediatric Lyme Disease Study Group. Lyme disease in children in southeastern Connecticut. N Engl J Med.1996;335:1270\u20131274","DOI":"10.1056\/NEJM199610243351703"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/1173\/995845\/pe0602001173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/6\/1173\/995845\/pe0602001173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:28:07Z","timestamp":1639146487000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/6\/1173\/64133\/Comparative-Study-of-Cefuroxime-Axetil-Versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2002,6,1]]},"published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.6.1173","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}